With two recent clinical-stage failures in Alzheimer’s disease, Eli Lilly & Co. is turning to a risk-sharing collaboration with AstraZeneca PLC to develop and commercialize AstraZeneca’s oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293 for the treatment of Alzheimer’s disease.
The companies announced the deal Sept. 16, which puts Lilly back in the mid-stage BACE inhibitor development game.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?